echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Cabozantinib Monotherapy for Advanced Soft Tissue Sarcoma

    Clin Cancer Res: Cabozantinib Monotherapy for Advanced Soft Tissue Sarcoma

    • Last Update: 2022-02-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Soft tissue sarcoma (STS) is a rare and heterogeneous stromal tumor


    We conducted an open-label, multi-institution, single-arm, phase II clinical trial of single cabozantinib in patients with aggressive advanced STS who had received at least one standard systemic therapy


    The primary endpoints were overall response rate and 6-month progression-free survival (PFS)


    Assess the patient's best response

    Assess the patient's best response

    The median treatment course was 4 (range 1-99)


    Objective responses (all partial responses) were achieved in 6 (11.


    progression-free survival

    progression-free survival

    The most common grade 3-4 adverse reactions were hypertension (7.


    side effects

    side effects

    In conclusion, cabozantinib alone has demonstrated modest resistance in STS patients with specific histologic subtypes (alveolar soft sarcoma, undifferentiated pleomorphic sarcoma, extraskeletal myxoid chondrosarcoma, and leiomyosarcoma).


    Cabozantinib showed certain antitumor activity as a single drug Cabozantinib showed certain antitumor activity

    Original source:

    Original source:

    Geraldine O'Sullivan Coyne, et al.




    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.